CommercialCoverageMedium impact
08.00.50af, Rituximab (Rituxan®) Infusion and Related Biosimilars, and Rituximab/Hyaluronidase Human for Subcutaneous Injection (Rituxan Hycela®)
Independence Blue Cross·Oncology, Hematology, Rheumatology·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Independence Blue Cross has updated their policy for Rituximab (Rituxan®) infusion, related biosimilars, and subcutaneous injection (Rituxan Hycela®) affecting both coverage/reimbursement positions and medical coding requirements. This pharmacy policy change will impact how these specialized medications are billed and covered.
Action Required
Before January 1, 2026: Billing team must review and update coding practices for Rituximab infusions and subcutaneous injections according to the new Independence Blue Cross policy. Access the full policy at the provided URL to understand specific coverage and reimbursement changes. Update billing software and encounter forms to reflect any new coding requirements for these specialty medications.